In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Still Time To File: Potential NDA/BLA Candidates In Queue For 2014

Executive Summary

Potentially, 38 drugs are in queue to be filed for approval in the US before the year’s end, according to Informa’s BioMedTracker. Which drugs are the most likely candidates?

You may also be interested in...



New Molecular Entities Approved In 2014

Annual listing of novel drugs cleared by FDA’s Center for Drug Evaluation and Research.

Biologics Approved In 2014

FDA transferred review of most therapeutic biologics to the Center for Drug Evaluation & Research in 2003. The Center for Biologics Evaluation & Research continues to review other biologics, including vaccines, cellular products, antitoxins and immunoglobulins.

New Drugs In 2013 Show A Virtuous Cycle: First-Cycle Approvals Up, Review Times Down

Even with half of CDER’s approvals qualifying for longer review timeframes under “the program,” the average time from submission to approval continued its multi-year decline, helped by a record high level of first-cycle approvals. Small molecules and big pharma dominated the 2013 class.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel